Related Experiment Video
Updated: Jan 25, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Histiocytic Sarcoma
1From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dr Hung); and Fine Needle Aspiration Service, Brigham and Women's Hospital, Boston, Massachusetts, the Department of Pathology, Harvard Medical School, Boston, Massacusetts, and Bone and Soft Tissue Pathology Service, Dana Farber Cancer Institute, Boston, Massachusetts (Dr Qian).
Abstract:
Histiocytic sarcoma, a rare malignant neoplasm showing morphologic and immunophenotypic features of histiocytes, is characterized typically by extranodal presentation and a dismal clinical course, particularly in patients with disseminated disease. A history of hematolymphoid disorder can be identified in a subset of patients, suggesting transdifferentiation of a preexisting hematolymphoid neoplasm in its pathogenesis. The differential diagnosis of histiocytic sarcoma includes various lymphomas, other histiocytic and dendritic cell neoplasms, carcinomas, melanomas, and pleomorphic sarcomas. Given its rarity and histologic overlap with diverse mimics, the diagnosis of histiocytic sarcoma can be extremely challenging. Recognition of morphologic clues, as well as judicious application of immunohistochemical markers to confirm its histiocytic lineage and to exclude mimics, is crucial for the diagnosis. Recent molecular studies by targeted next-generation sequencing identified recurrent alterations in the mitogen-activated protein (MAP) kinase pathway and chromatin regulators in the pathogenesis of histiocytic sarcoma and may suggest possible therapeutic targets.

